Patents by Inventor Rongyuan Xie

Rongyuan Xie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted imidazole derivatives and methods of use thereof
    Patent number: 10363241
    Abstract: The present invention provides intermediates for methods for synthesizing compounds of Formula (I) and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: July 30, 2019
    Assignee: vTv Therapeutics LLC
    Inventors: David Jones, Raju Bore Gowda, Rongyuan Xie
  • Substituted Imidazole Derivatives and Methods of Use Thereof
    Publication number: 20190076402
    Abstract: The present invention provides intermediates for methods for synthesizing compounds of Formula (I) and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: November 9, 2018
    Publication date: March 14, 2019
    Inventors: David Jones, Raju Bore Gowda, Rongyuan Xie
  • Substituted Imidazole Derivatives and Methods of Use Thereof
    Publication number: 20170157093
    Abstract: The present invention provides imidazole derivatives of Formula (I) and pharmaceutically acceptable salts thereof. and their use in the treatment of diseases.
    Type: Application
    Filed: February 21, 2017
    Publication date: June 8, 2017
    Inventors: David Jones, Raju Bore Gowda, Rongyuan Xie
  • Substituted imidazole derivatives and methods of use thereof
    Patent number: 9598375
    Abstract: The present invention provides imidazole derivatives of Formula (I) and pharmaceutically acceptable salts thereof. and their use in the treatment of diseases such as Alzheimer's Disease.
    Type: Grant
    Filed: October 9, 2013
    Date of Patent: March 21, 2017
    Assignee: vTv Therapeutics LLC
    Inventors: David Jones, Raju Bore Gowda, Rongyuan Xie
  • Phenyl-heteroaryl derivatives and methods of use thereof
    Patent number: 9045461
    Abstract: The present invention provides phenyl-heteroaryl derivatives of Formula (I) and pharmaceutically acceptable salts thereof These compounds are useful in the treatment of RAGE-mediated diseases. The present invention further relates to methods for the preparation of compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds, and the use of such compounds and/or pharmaceutical compositions in treating RAGE-mediated diseases.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: June 2, 2015
    Assignee: TransTech Pharma, LLC
    Inventors: Devi R. Gohimukkula, David Jones, Ghassan Qabaja, Jeff J. Zhu, Jeremy T. Cooper, William K. Banner, Kurt Sundermann, Muralidhar Bondlela, Mohan Rao, Pingzhen Wang, Raju B. Gowda, Robert C. Andrews, Suparna Gupta, Anitha Hari, Rongyuan Xie
  • Phenyl-Heteroaryl Derivatives and Methods of Use Thereof
    Publication number: 20140206660
    Abstract: The present invention provides phenyl-heteroaryl derivatives of Formula (I) and pharmaceutically acceptable salts thereof These compounds are useful in the treatment of RAGE-mediated diseases. The present invention further relates to methods for the preparation of compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds, and the use of such compounds and/or pharmaceutical compositions in treating RAGE-mediated diseases.
    Type: Application
    Filed: March 26, 2014
    Publication date: July 24, 2014
    Applicant: TransTech Pharma, LLC
    Inventors: Devi R. Gohimukkula, David Jones, Ghassan Qabaja, Jeff J. Zhu, Jeremy T. Cooper, William K. Banner, Kurt Sundermann, Muralidhar Bondlela, Mohan Rao, Pingzhen Wang, Raju B. Gowda, Robert C. Andrews, Suparna Gupta, Anitha Hari, Rongyuan Xie
  • Phenyl-heteroaryl derivatives and methods of use thereof
    Patent number: 8741900
    Abstract: The present invention provides phenyl-heteroaryl derivatives of Formula (I) and pharmaceutically acceptable salts thereof These compounds are useful in the treatment of RAGE-mediated diseases such as Alzheimer's Disease. The present invention further relates to methods for the preparation of compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds, and the use of such compounds and/or pharmaceutical compositions in treating RAGE-mediated diseases.
    Type: Grant
    Filed: February 21, 2013
    Date of Patent: June 3, 2014
    Assignee: TransTech Pharma, LLC
    Inventors: Devi R. Gohimukkula, David Jones, Ghassan Qabaja, Jeff J. Zhu, Jeremy T. Cooper, William K. Banner, Kurt Sundermann, Muralidhar Bondlela, Mohan Rao, Pingzhen Wang, Raju B. Gowda, Robert C. Andrews, Suparna Gupta, Anitha Hari, Rongyuan Xie
  • Substituted Imidazole Derivatives and Methods of Use Thereof
    Publication number: 20140039025
    Abstract: The present invention provides imidazole derivatives of Formula (I) and pharmaceutically acceptable salts thereof. and their use in the treatment of diseases such as Alzheimer's Disease.
    Type: Application
    Filed: October 9, 2013
    Publication date: February 6, 2014
    Applicant: TransTech Pharma, Inc.
    Inventors: David Jones, Raju Bore Gowda, Rongyuan Xie
  • Substituted imidazole derivatives and methods of use thereof
    Patent number: 8580833
    Abstract: The present invention provides imidazole derivatives of Formula (I) and pharmaceutically acceptable salts thereof. These compounds are useful in the treatment of RAGE-mediated diseases such as Alzheimer's Disease. The present invention further relates to methods for the preparation of compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds, and the use the such compounds and/or pharmaceutical compositions in treating RAGE-mediated diseases.
    Type: Grant
    Filed: September 23, 2010
    Date of Patent: November 12, 2013
    Assignee: TransTech Pharma, Inc.
    Inventors: David Jones, Raju Bore Gowda, Rongyuan Xie
  • Substituted imidazo[1,2-b]pyridazine derivatives, pharmaceutical compositions, and methods of use as ?-secretase inhibitors
    Patent number: 8450354
    Abstract: The present invention provides substituted imidazo[1,2-b]pyridazine derivatives, pharmaceutically acceptable salts thereof, and tautomers of any of the foregoing, where such compounds inhibit ?-site amyloid precursor protein-cleaving enzyme (BACE), which may be useful in the treatment of diseases in which BACE is involved, such as Alzheimer's disease. The invention also provides pharmaceutical compositions comprising any of these compounds and the use of any of these compounds and compositions in the treatment of diseases, disorders, or conditions in which BACE is involved.
    Type: Grant
    Filed: March 21, 2011
    Date of Patent: May 28, 2013
    Assignee: High Point Pharmaceuticals, LLC
    Inventors: Adnan M. M. Mjalli, Anitha Hari, Bapu Gaddam, Devi Reddy Gohimukkula, Dharma Rao Polisetti, Mohan Rao, Raju Bore Gowda, Robert Carl Andrews, Rongyuan Xie, Soumya P. Sahoo, Tan Ren, William Kenneth Banner
  • Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors
    Patent number: 8404731
    Abstract: The present invention provides imidazole derivatives of Formula (I-IV), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I-IV), and their use in treating human or animal disorders. The compounds of the invention inhibit protein tyrosine phosphatase 1B and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes and Type II diabetes.
    Type: Grant
    Filed: January 11, 2010
    Date of Patent: March 26, 2013
    Assignee: TransTech Pharma, Inc.
    Inventors: Adnan M. M. Mjalli, Dharma R. Polisetti, Govindan Subramanian, James C. Quada, Ravindra R. Yarragunta, Robert C. Andrews, Rongyuan Xie
  • Substituted isoquinoline derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors
    Patent number: 8350039
    Abstract: The present invention is directed to substituted isoquinoline derivatives, pharmaceutically acceptable salts thereof, and tautomers of such compounds or salts, that inhibit ?-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which BACE is involved.
    Type: Grant
    Filed: August 22, 2011
    Date of Patent: January 8, 2013
    Assignee: High Point Pharmaceuticals, LLC
    Inventors: Adnan M. M. Mjalli, Bapu Gaddam, Devi Reddy Gohimukkula, Dharma Rao Polisetti, Hassan El Abdellaoui, Mohan Rao, Pingzhen Wang, Robert Carl Andrews, Rongyuan Xie, Tan Ren
  • Substituted Imidazole Derivatives, Compositions, and Methods of Use as PTPase Inhibitors
    Publication number: 20120196906
    Abstract: The present invention provides imidazole derivatives of Formula (I-IV), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I-IV), and their use in treating human or animal disorders. The compounds of the invention inhibit protein tyrosine phosphatase 1B and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes and Type II diabetes.
    Type: Application
    Filed: March 6, 2012
    Publication date: August 2, 2012
    Applicant: TransTech Pharma, Inc.
    Inventors: Adnan M.M. Mjalli, Dharma R. Polisetti, Govindan Subramanian, James C. Quada, Ravindra R. Yarragunta, Robert C. Andrews, Rongyuan Xie
  • SUBSTITUTED ISOQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS
    Publication number: 20120101125
    Abstract: The present invention is directed to substituted isoquinoline derivatives, pharmaceutically acceptable salts thereof, and tautomers of such compounds or salts, that inhibit ?-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which BACE is involved.
    Type: Application
    Filed: August 22, 2011
    Publication date: April 26, 2012
    Applicant: HIGH POINT PHARMACEUTICALS, LLC
    Inventors: Adnan M. M. Mjalli, Bapu Gaddam, Devi Reddy Gohimukkula, Dharma Rao Polisetti, Hassan El Abdellaoui, Mohan Rao, Pingzhen Wang, Robert Carl Andrews, Rongyuan Xie, Tan Ren
  • SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS
    Publication number: 20120101093
    Abstract: The present invention is directed to substituted imidazo[1,2-a]pyridine derivatives, pharmaceutically acceptable salts thereof, and tautomers of such compounds or salts, that inhibit ?-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which BACE is involved.
    Type: Application
    Filed: August 22, 2011
    Publication date: April 26, 2012
    Applicant: HIGH POINT PHARMACEUTICALS, LLC
    Inventors: Adnan M. M. Mjalli, Anitha Hari, Bapu Gaddam, Devi Reddy Gohimukkula, Dharma Rao Polisetti, Hassan El Abdellaoui, Mohan Rao, Robert Carl Andrews, Rongyuan Xie, Tan Ren
  • SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS
    Publication number: 20110237570
    Abstract: The present invention provides substituted imidazo[1,2-b]pyridazine derivatives, pharmaceutically acceptable salts thereof, and tautomers of any of the foregoing, where such compounds inhibit ?-site amyloid precursor protein-cleaving enzyme (BACE), which may be useful in the treatment of diseases in which BACE is involved, such as Alzheimer's disease. The invention also provides pharmaceutical compositions comprising any of these compounds and the use of any of these compounds and compositions in the treatment of diseases, disorders, or conditions in which BACE is involved.
    Type: Application
    Filed: March 21, 2011
    Publication date: September 29, 2011
    Applicant: HIGH POINT PHARMACEUTICALS, LLC
    Inventors: Adnan M.M. Mjalli, Anitha Hari, Bapu Gaddam, Devi Reddy Gohimukkula, Dharma Rao Polisetti, Mohan Rao, Raju Bore Gowda, Robert Carl Andrews, Rongyuan Xie, Soumya P. Sahoo, Tan Ren, William Kenneth Banner
  • Substituted Imidazole Derivatives And Methods Of Use Thereof
    Publication number: 20110105578
    Abstract: The present invention provides imidazole derivatives of Formula (I) and pharmaceutically acceptable salts thereof. These compounds are useful in the treatment of RAGE-mediated diseases such as Alzheimer's Disease. The present invention further relates to methods for the preparation of compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds, and the use the such compounds and/or pharmaceutical compositions in treating RAGE-mediated diseases.
    Type: Application
    Filed: September 23, 2010
    Publication date: May 5, 2011
    Inventors: David Jones, Raju Bore Gowda, Rongyuan Xie
  • Substituted Azole Derivatives, Compositions, and Methods of Use
    Publication number: 20110092553
    Abstract: The present invention provides azole derivatives of Formula (I), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I), and their use in treating human or animal disorders. The compounds of the invention can be useful as inhibitors of protein tyrosine phosphatases and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes and Type II diabetes.
    Type: Application
    Filed: November 19, 2010
    Publication date: April 21, 2011
    Applicant: TransTech Pharma, Inc.
    Inventors: Adnan M.M. Mjalli, Dharma R. Polisetti, Govindan Subramanian, James C. Quada, JR., Murty N. Arimilli, Ravindra R. Yarragunta, Robert C. Andrews, Rongyuan Xie
  • Substituted Azole Derivatives as Therapeutic Agents
    Publication number: 20110077399
    Abstract: This invention provides azoles which may be useful as inhibitors of protein tyrosine phosphatases (PTPases). The present invention provides compounds of Formula (I), methods of their preparation, pharmaceutical compositions comprising the compounds and their use in treating human or animal disorders. The compounds of the invention may be useful as inhibitors of protein tyrosine phosphatases and thus can be useful for the management, treatment, control and adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes, Type II diabetes.
    Type: Application
    Filed: December 1, 2010
    Publication date: March 31, 2011
    Applicant: TRANSTECH PHARMA, INC.
    Inventors: Adnan M. M. Mjalli, Robert C. Andrews, Ravindra R. Yarragunta, Rongyuan Xie, Govindan Subramanian, James C. Quada, JR., Murty N. Arimilli, Dharma R. Polisetti
  • Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors
    Patent number: 7723369
    Abstract: The present invention provides imidazole derivatives of Formula (I-IV), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I-IV), and their use in treating human or animal disorders. The compounds of the invention inhibit protein tyrosine phosphatase 1B and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes and Type II diabetes.
    Type: Grant
    Filed: January 30, 2007
    Date of Patent: May 25, 2010
    Assignee: TransTech Pharma, Inc.
    Inventors: Adnan M. M. Mjalli, Dharma R. Polisetti, Govindan Subramanian, James C. Quada, Ravindra R. Yarragunta, Robert C. Andrews, Rongyuan Xie